Paid Clinical Trials Overland Park

Discover 772 paid clinical trials in Overland Park, Kansas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 772

Observational StudyRegistry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction

Recruiting

Sponsor:

Axogen Corporation

Location:

Kansas City KS, Columbia MO, Omaha NE, Germantown TNshow 33 more

Code:

NCT01526681

Conditions

Peripheral Nerve Injuries

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

Interventions

Processed Human Nerve Graft

Standard Treatment, Autogenous Nerve Graft, Direct Suture, etc.

Autogenous Nerve Graft

Nerve Tube Conduit

Autologous Breast Reconstruction with Neurotization

ASP2138 with Cancer TreatmentsA Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Recruiting

PHASE1

Sponsor:

Astellas Pharma Global Development, Inc.

Location:

Westwood KS, Chicago IL, Dallas TX, Milwaukee WIshow 7 more

Code:

NCT05365581

Conditions

Gastric Adenocarcinoma

Gastroesophageal Junction (GEJ) Adenocarcinoma

Pancreatic Adenocarcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ASP2138

Pembrolizumab

Oxaliplatin

Leucovorin

Fluorouracil

Remibrutinib vs. TeriflunomideEfficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting

PHASE3

Sponsor:

Novartis Pharmaceuticals

Location:

Kansas City KS, Kansas City MO, Sherman TX, Frisco TXshow 59 more

Code:

NCT05156281

Conditions

Relapsing Multiple Sclerosis

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Not accepted

Interventions

Remibrutinib

Teriflunomide

LY3556050A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain

Recruiting

PHASE2

Sponsor:

Eli Lilly and Company

Location:

Kansas City MO, Springfield MO, Wichita KS, Saint Peters MOshow 29 more

Code:

NCT06074562

Conditions

Diabetic Peripheral Neuropathy

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

LY3556050

Placebo

Observational StudyLGMD R1 Natural History Study

Recruiting

Sponsor:

Virginia Commonwealth University

Location:

Kansas City KS, Saint Louis MO, Iowa City IA, Minneapolis MNshow 6 more

Code:

NCT05618080

Conditions

Calpain-3 Deficiency Limb Girdle Muscular Dystrophy Type 2A

Limb Girdle Muscular Dystrophy

Limb Girdle Muscular Dystrophy Type R1

LGMD2A

Eligibility Criteria

Sex: All

Age: 12 - 50

Healthy Volunteers: Not accepted

Crenolanib vs. MidostaurinStudy of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

Recruiting

PHASE3

Sponsor:

Arog Pharmaceuticals, Inc.

Location:

Kansas City KS, Iowa City IA, Chicago IL, Minneapolis MNshow 17 more

Code:

NCT03258931

Conditions

Newly Diagnosed FLT3 Mutated AML

Eligibility Criteria

Sex: All

Age: 18 - 60

Healthy Volunteers: Not accepted

Interventions

Crenolanib

Midostaurin

Cytarabine

Duanorubicin

Observational StudyContinuous Monitoring and Control of Hypoglycemia

Recruiting

Sponsor:

DexCom, Inc.

Location:

Kansas City MO, Topeka KS, Omaha NE, Des Moines IAshow 20 more

Code:

NCT03340831

Conditions

Diabetes

Eligibility Criteria

Sex: All

Age: 2+

Healthy Volunteers: Not accepted

Interventions

Continuous Glucose Monitoring (CGM)

BIIB091 & DRFA Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

Recruiting

PHASE2

Sponsor:

Biogen

Location:

Kansas City KS, Saint Louis MO, Cordova TN, Madison WIshow 19 more

Code:

NCT05798520

Conditions

Relapsing Forms of Multiple Sclerosis

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Not accepted

Interventions

BIIB091

DRF

Placebo

Talquetamab, Daratumumab, PomalidomideA Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

Recruiting

PHASE3

Sponsor:

Janssen Research & Development, LLC

Location:

Westwood KS, Saint Louis MO, Little Rock AR, Memphis TNshow 29 more

Code:

NCT05455320

Conditions

Relapsed or Refractory Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Talquetamab

Daratumumab

Pomalidomide

Dexamethasone

PegozaferminA Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

Recruiting

PHASE3

Sponsor:

89bio, Inc.

Location:

Topeka KS, Iowa City IA, North Little Rock AR, Little Rock ARshow 89 more

Code:

NCT06419374

Conditions

Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Pegozafermin

Placebo